SEC Form 10-Q filed by Medtronic plc.
$MDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/30/2025 | Underperform → Peer Perform | Wolfe Research | |
| 6/16/2025 | $110.00 | Outperform | Leerink Partners |
| 3/4/2025 | $92.00 → $107.00 | Neutral → Buy | Citigroup |
| 10/10/2024 | $98.00 → $105.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/21/2024 | $92.00 → $94.00 | Perform | Oppenheimer |
| 8/15/2024 | $76.00 → $90.00 | Sell → Neutral | UBS |
| 8/14/2024 | $100.00 → $85.00 | Buy → Hold | Stifel |
| 5/30/2024 | $83.00 | Sell | Goldman |
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
8-K - Medtronic plc (0001613103) (Filer)
PRE 14A - Medtronic plc (0001613103) (Filer)
25-NSE - Medtronic plc (0001613103) (Subject)
Experienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors Board forms new Growth and Operating committees to sharpen focus on the company's ongoing strategic portfolio management, operational execution and capital allocation Plan to host Investor Day in 2026 Initiatives follow constructive engagement with Elliott Management GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the Medtronic Board of Directors has appointed John Groetelaars and Bill Jellison as independent directors, effective immediately. Consistent with the company's commitment to shareholder value creation, and
11th quarter in a row of mid-single digit organic revenue growth;Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Key Highlights Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8% organicGAAP diluted EPS of $0.81 increased 1%; non-GAAP diluted EPS of $1.26 increased 2%Company raises FY26 EPS guidance; reiterates FY26 organic revenue growth guidanceCardiac Ablation Solutions revenue increased nearly 50%, incl
GALWAY, Ireland, Aug. 14, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 14, 2025, approved the company's cash dividend for the second quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc,
Wolfe Research upgraded Medtronic from Underperform to Peer Perform
Leerink Partners initiated coverage of Medtronic with a rating of Outperform and set a new price target of $110.00
Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously
11th quarter in a row of mid-single digit organic revenue growth;Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Key Highlights Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8% organicGAAP diluted EPS of $0.81 increased 1%; non-GAAP diluted EPS of $1.26 increased 2%Company raises FY26 EPS guidance; reiterates FY26 organic revenue growth guidanceCardiac Ablation Solutions revenue increased nearly 50%, incl
GALWAY, Ireland, Aug. 14, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 14, 2025, approved the company's cash dividend for the second quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc,
GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart
GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent. Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu
GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)